CTOs on the Move

Akoya Biosciences

www.akoyabio.com

 
As The Spatial Biology Company®, Akoya Biosciences` mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.akoyabio.com
  • 100 Campus Drive 6th Floor
    Marlborough, MA USA 01752
  • Phone: 855.896.8401

Executives

Name Title Contact Details
Jeff Radin
Director of IT Profile

Funding

Akoya Biosciences raised $24.5M on 09/26/2018
Akoya Biosciences raised $50M on 12/05/2019

Similar Companies

Odyssey Thera FKA: Odyssey Pharmaceuticals

Odyssey Thera FKA: Odyssey Pharmaceuticals is a San Ramon, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cortendo AB

Cortendo AB is a global biopharmaceutical company founded in 1996, incorporated in Sweden, and based in the United States. Cortendo recognizes the urgent need to make new medicines available for people with orphan diseases, and the Company is committed to delivering therapies that make a difference. An orphan disease is one for which the pharmaceutical industry has not worked to make new medicines. It may be a rare disease (in the U.S. this is defined as a disease that affects fewer than 200,000 people) or a disease such as tuberculosis, cholera, typhoid or malaria that is not often diagnosed in developed countries but remains common in countries that are still developing. Cortendo’s initial strategic goal is to be the global leader in finding, developing and making medicines for people with orphan endocrine diseases, with its most advanced program in Cushing’s syndrome. Cortendo research led to the development of COR-003 (levoketoconazole) which is currently being studied in the Phase 3 global SONICS trial for the treatment of endogenous Cushing’s syndrome. COR-003 has received orphan designation from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Cortendo is building the capabilities and resources to independently develop and commercialize its orphan assets in key global markets and to partner non-strategic product opportunities, such as BioPancreate-2001 for Type 1 and Type 2 diabetes. The company also intends to leverage its commercial expertise by working with partners to acquire, develop, and commercialize late-stage or commercial assets in a select few orphan disease focus areas.  

NewNeural

NewNeural is a Naperville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Standards Testing Laboratory

STL now operates the world's largest independent dynamic testing facility for tires, wheels and related automotive components, providing the rubber and automotive industries with dynamic laboratory testing, static and physical testing, fleet testing,

Deltagen

Deltagen is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.